Novel radioligand therapy proven superior for metastatic prostate cancer patients
A novel prostate cancer treatment—225Ac-PSMA-617 radioligand therapy—has been shown to increase the progression free survival (PFS) and overall survival (OS) of metastatic castration-resistant prostate cancer (mCRPC) ...
Mar 9, 2022
0
3